ADAG News

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

Eco DC Solutions, du Groupe Adag, obtient 30 turbines à gaz Dongfang et libère plus de 2,1 GW pour les centres de données canadiens

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Adagene to Participate in Three Upcoming Investor Conferences

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer